DE60030338D1 - Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen Salzen - Google Patents

Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen Salzen

Info

Publication number: DE60030338D1
Authority: DE; Germany
Prior art keywords: carbamoylbenzofuran; cyanoindol; piperazine; butyl; acceptable salts
Prior art date: 1999-05-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60030338T

Other languages

English (en)

Other versions

DE60030338T2 (de

Inventor

Gerd Bartoszyk

Christoph Seyfried

Amsterdam Christoph Van

Henning Boettcher

Ewen Sedman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Patent GmbH

Original Assignee

Merck Patent GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-27

Filing date

2000-05-16

Publication date

2006-10-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60030338(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-16 Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH

2006-10-05 Application granted granted Critical

2006-10-05 Publication of DE60030338D1 publication Critical patent/DE60030338D1/de

2007-08-16 Publication of DE60030338T2 publication Critical patent/DE60030338T2/de

2020-05-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Obesity (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Addiction (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DE60030338T 1999-05-27 2000-05-16 Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen Salzen Expired - Lifetime DE60030338T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99109295		1999-05-27
EP99109295		1999-05-27

Publications (2)

Publication Number	Publication Date
DE60030338D1 true DE60030338D1 (de)	2006-10-05
DE60030338T2 DE60030338T2 (de)	2007-08-16

Family

ID=8238153

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE60042710T Expired - Lifetime DE60042710D1 (de)	1999-05-27	2000-05-16	Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und dessem physiologisch akzeptablen Salzen
DE60009697T Expired - Lifetime DE60009697T2 (de)	1999-05-27	2000-05-16	Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
DE60030338T Expired - Lifetime DE60030338T2 (de)	1999-05-27	2000-05-16	Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen Salzen

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE60042710T Expired - Lifetime DE60042710D1 (de)	1999-05-27	2000-05-16	Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und dessem physiologisch akzeptablen Salzen
DE60009697T Expired - Lifetime DE60009697T2 (de)	1999-05-27	2000-05-16	Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie

Country Status (31)

Country	Link
US (4)	US6900212B1 (de)
EP (3)	EP1185272B1 (de)
JP (2)	JP4884588B2 (de)
KR (1)	KR100683367B1 (de)
CN (3)	CN101869565A (de)
AR (1)	AR024112A1 (de)
AT (3)	ATE438399T1 (de)
AU (1)	AU771778B2 (de)
BR (1)	BR0010948A (de)
CA (3)	CA2694866A1 (de)
CY (2)	CY1105750T1 (de)
CZ (1)	CZ295623B6 (de)
DE (3)	DE60042710D1 (de)
DK (3)	DK1736158T3 (de)
ES (3)	ES2271707T3 (de)
HK (1)	HK1048444B (de)
HU (1)	HU229059B1 (de)
IL (2)	IL146707A0 (de)
MX (1)	MXPA01012172A (de)
MY (1)	MY135627A (de)
NO (2)	NO322120B1 (de)
PL (3)	PL199650B1 (de)
PT (3)	PT1185272E (de)
RU (1)	RU2237477C2 (de)
SI (2)	SI1410800T1 (de)
SK (1)	SK287851B6 (de)
TR (1)	TR200103361T2 (de)
TW (1)	TW518218B (de)
UA (1)	UA74337C2 (de)
WO (1)	WO2000072832A2 (de)
ZA (1)	ZA200110485B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW518218B (en) *	1999-05-27	2003-01-21	Merck Patent Gmbh	Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) *	2000-11-20	2006-07-17	Merck Patent Gmbh	Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de)	2001-03-14	2002-09-19	Merck Patent Gmbh	Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) *	2001-06-19	2006-09-15	Мерк Патент Гмбх	Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) *	2002-04-16	2003-11-06	Merck Patent Gmbh	Substituierte Indole
DE10305739A1 (de)	2003-02-11	2004-08-19	Merck Patent Gmbh	Benzofuranderivate
WO2004082686A2 (en) *	2003-03-13	2004-09-30	Dynogen Pharmaceuticals, Inc.	Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
US7893261B2 (en)	2004-03-26	2011-02-22	Baylor University	Serotonin reuptake inhibitors
US8003676B2 (en)	2006-05-30	2011-08-23	Astrazeneca Ab	1,3,4-oxadiazole derivatives as DGAT1 inhibitors
WO2009081195A1 (en)	2007-12-20	2009-07-02	Astrazeneca Ab	Carbamoyl compounds as dgat1 inhibitors 190
CA2764013A1 (en)	2009-06-19	2010-12-23	Astrazeneca Ab	Pyrazine carboxamides as inhibitors of dgat1
US8927602B2 (en)	2009-11-06	2015-01-06	Sk Biopharmaceuticals Co., Ltd.	Methods for treating fibromyalgia syndrome
KR101783632B1 (ko)	2009-11-06	2017-10-10	에스케이바이오팜 주식회사	주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US8623913B2 (en)	2010-06-30	2014-01-07	Sk Biopharmaceuticals Co., Ltd.	Methods for treating restless legs syndrome
US9610274B2 (en)	2010-06-30	2017-04-04	Sk Biopharmaceuticals Co., Ltd.	Methods for treating bipolar disorder
TWI577377B (zh) *	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
US9708300B2 (en)	2011-03-20	2017-07-18	Cadila Healthcare Limited	Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) *	2011-08-30	2013-03-06	天津药物研究院	一种含有效成分盐酸维拉佐酮的缓释片
CA2876741A1 (en)	2012-06-13	2013-12-19	Apotex Inc.	Forms of vilazodone and processes for the preparation thereof
CN102860993A (zh) *	2012-10-16	2013-01-09	北京诚创思达医药科技有限公司	一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en)	2012-10-22	2014-05-01	Cadila Healthcare Limited	Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) *	2012-12-17	2013-03-20	南京海纳医药科技有限公司	1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
CA3216579A1 (en)	2013-01-22	2014-07-31	Vistagen Therapeutics, Inc.	Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP2824104A1 (de)	2013-07-12	2015-01-14	Sandoz AG	Verfahren zur Herstellung von Form III von Vilazodonhydrochlorid
SG10202007661XA (en) *	2015-05-22	2020-09-29	Vistagen Therapeutics Inc	Therapeutic uses of l-4-chlorokynurenine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2672052B1 (fr) *	1991-01-28	1995-05-24	Esteve Labor Dr	Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) *	1992-04-21	1992-04-21	Kabi Pharmacia Ab	Agents for treating substance abuse disorders
DE4333254A1 (de)	1993-09-30	1995-04-06	Merck Patent Gmbh	Piperidine und Piperazine
GB9406857D0 (en) *	1994-04-07	1994-06-01	Sandoz Ltd	Improvements in or relating to organic compounds
DE19514567A1 (de) *	1995-04-20	1996-10-24	Merck Patent Gmbh	Benzofurane
US5763457A (en) *	1995-11-13	1998-06-09	Eli Lilly And Company	Method for treating anxiety
US5914394A (en) *	1997-03-27	1999-06-22	Millenium Pharmaceuticals, Inc.	Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) *	1997-06-19	1999-05-04	Cole; William L.	Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) *	1998-03-09	2002-10-29	Pirelli Pneumatici S.P.A.	Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr)	1998-07-28	2000-02-04	Synthelabo	Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) *	1999-05-27	2003-01-21	Merck Patent Gmbh	Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612563A3 (de) *	2001-09-11	2009-12-09	JTEKT Corporation	Magnetring zur Erzeugung von Impulsen
FR2844591B1 (fr) *	2002-09-13	2005-04-15	Arvinmeritor Light Vehicle Sys	Dispositif de determination du deplacement d'un arbre

1999
- 1999-11-15 TW TW088119882A patent/TW518218B/zh not_active IP Right Cessation
2000
- 2000-05-16 DE DE60042710T patent/DE60042710D1/de not_active Expired - Lifetime
- 2000-05-16 HK HK03100617.0A patent/HK1048444B/zh not_active IP Right Cessation
- 2000-05-16 ES ES04001441T patent/ES2271707T3/es not_active Expired - Lifetime
- 2000-05-16 WO PCT/EP2000/004376 patent/WO2000072832A2/en not_active Ceased
- 2000-05-16 CA CA2694866A patent/CA2694866A1/en not_active Abandoned
- 2000-05-16 RU RU2001133342A patent/RU2237477C2/ru not_active IP Right Cessation
- 2000-05-16 US US09/979,922 patent/US6900212B1/en not_active Expired - Lifetime
- 2000-05-16 PL PL383406A patent/PL199650B1/pl unknown
- 2000-05-16 AU AU50663/00A patent/AU771778B2/en not_active Ceased
- 2000-05-16 TR TR2001/03361T patent/TR200103361T2/xx unknown
- 2000-05-16 DK DK06017231T patent/DK1736158T3/da active
- 2000-05-16 CZ CZ20014226A patent/CZ295623B6/cs not_active IP Right Cessation
- 2000-05-16 BR BR0010948-7A patent/BR0010948A/pt not_active Application Discontinuation
- 2000-05-16 MX MXPA01012172A patent/MXPA01012172A/es active IP Right Grant
- 2000-05-16 CN CN200910113677A patent/CN101869565A/zh active Pending
- 2000-05-16 CA CA002372668A patent/CA2372668C/en not_active Expired - Fee Related
- 2000-05-16 AT AT06017231T patent/ATE438399T1/de active
- 2000-05-16 DK DK04001441T patent/DK1410800T3/da active
- 2000-05-16 PT PT00935031T patent/PT1185272E/pt unknown
- 2000-05-16 IL IL14670700A patent/IL146707A0/xx active IP Right Grant
- 2000-05-16 KR KR1020017015141A patent/KR100683367B1/ko not_active Expired - Fee Related
- 2000-05-16 JP JP2000620944A patent/JP4884588B2/ja not_active Expired - Fee Related
- 2000-05-16 PL PL383006A patent/PL200490B1/pl unknown
- 2000-05-16 AT AT00935031T patent/ATE263564T1/de active
- 2000-05-16 SI SI200030902T patent/SI1410800T1/sl unknown
- 2000-05-16 UA UA2001128861A patent/UA74337C2/uk unknown
- 2000-05-16 CN CNB008081352A patent/CN1198618C/zh not_active Expired - Fee Related
- 2000-05-16 DE DE60009697T patent/DE60009697T2/de not_active Expired - Lifetime
- 2000-05-16 SI SI200030423T patent/SI1185272T1/xx unknown
- 2000-05-16 EP EP00935031A patent/EP1185272B1/de not_active Expired - Lifetime
- 2000-05-16 DE DE60030338T patent/DE60030338T2/de not_active Expired - Lifetime
- 2000-05-16 PT PT06017231T patent/PT1736158E/pt unknown
- 2000-05-16 ES ES06017231T patent/ES2330774T3/es not_active Expired - Lifetime
- 2000-05-16 SK SK1646-2001A patent/SK287851B6/sk not_active IP Right Cessation
- 2000-05-16 EP EP04001441A patent/EP1410800B1/de not_active Expired - Lifetime
- 2000-05-16 HU HU0201275A patent/HU229059B1/hu not_active IP Right Cessation
- 2000-05-16 CA CA2615271A patent/CA2615271C/en not_active Expired - Fee Related
- 2000-05-16 EP EP06017231A patent/EP1736158B1/de not_active Expired - Lifetime
- 2000-05-16 AT AT04001441T patent/ATE337008T1/de active
- 2000-05-16 PT PT04001441T patent/PT1410800E/pt unknown
- 2000-05-16 DK DK00935031T patent/DK1185272T3/da active
- 2000-05-16 ES ES00935031T patent/ES2219342T3/es not_active Expired - Lifetime
- 2000-05-16 PL PL352373A patent/PL199516B1/pl unknown
- 2000-05-16 CN CNA2005100544177A patent/CN1679577A/zh active Pending
- 2000-05-25 MY MYPI20002314A patent/MY135627A/en unknown
- 2000-05-26 AR ARP000102575A patent/AR024112A1/es unknown
2001
- 2001-11-22 IL IL146707A patent/IL146707A/en not_active IP Right Cessation
- 2001-11-26 NO NO20015746A patent/NO322120B1/no not_active IP Right Cessation
- 2001-12-20 ZA ZA200110485A patent/ZA200110485B/en unknown
2004
- 2004-11-23 US US10/994,226 patent/US7371756B2/en not_active Expired - Lifetime
2006
- 2006-04-06 NO NO20061562A patent/NO324230B1/no not_active IP Right Cessation
- 2006-11-02 CY CY20061101575T patent/CY1105750T1/el unknown
2007
- 2007-11-28 US US11/946,149 patent/US7642261B2/en not_active Expired - Fee Related
2009
- 2009-10-14 CY CY20091101063T patent/CY1109472T1/el unknown
- 2009-11-17 US US12/620,049 patent/US20100063062A1/en not_active Abandoned
2011
- 2011-02-10 JP JP2011027903A patent/JP2011148799A/ja active Pending

Also Published As

Publication number	Publication date
DE60030338T2 (de)	2007-08-16
US20100063062A1 (en)	2010-03-11
ZA200110485B (en)	2003-06-30
MXPA01012172A (es)	2002-07-22
CY1105750T1 (el)	2010-12-22
SK16462001A3 (sk)	2002-02-05
PL199516B1 (pl)	2008-09-30
HUP0201275A2 (en)	2002-08-28
EP1736158B1 (de)	2009-08-05
CA2615271A1 (en)	2000-12-07
EP1410800A1 (de)	2004-04-21
SK287851B6 (sk)	2012-01-04
CN1198618C (zh)	2005-04-27
NO20015746D0 (no)	2001-11-26
NO20061562L (no)	2001-11-26
DE60042710D1 (de)	2009-09-17
EP1736158A3 (de)	2007-01-03
DK1185272T3 (da)	2004-08-09
RU2237477C2 (ru)	2004-10-10
CA2615271C (en)	2011-02-15
NO322120B1 (no)	2006-08-14
ES2330774T3 (es)	2009-12-15
BR0010948A (pt)	2002-04-23
WO2000072832A3 (en)	2001-12-20
US7642261B2 (en)	2010-01-05
CA2372668C (en)	2009-11-03
CN1679577A (zh)	2005-10-12
US20050113386A1 (en)	2005-05-26
US6900212B1 (en)	2005-05-31
EP1736158A2 (de)	2006-12-27
PT1185272E (pt)	2004-08-31
CA2694866A1 (en)	2000-12-07
CA2372668A1 (en)	2000-12-07
EP1185272A2 (de)	2002-03-13
SI1410800T1 (sl)	2007-02-28
UA74337C2 (uk)	2005-12-15
ES2271707T3 (es)	2007-04-16
US7371756B2 (en)	2008-05-13
IL146707A0 (en)	2002-07-25
CN1361692A (zh)	2002-07-31
JP2011148799A (ja)	2011-08-04
WO2000072832A2 (en)	2000-12-07
CN101869565A (zh)	2010-10-27
TR200103361T2 (tr)	2002-05-21
CZ295623B6 (cs)	2005-09-14
HUP0201275A3 (en)	2004-04-28
DK1410800T3 (da)	2006-12-27
AR024112A1 (es)	2002-09-04
AU771778B2 (en)	2004-04-01
US20080119484A1 (en)	2008-05-22
NO20015746L (no)	2001-11-26
HK1048444B (zh)	2005-12-09
CZ20014226A3 (cs)	2002-03-13
ATE438399T1 (de)	2009-08-15
JP4884588B2 (ja)	2012-02-29
PT1410800E (pt)	2007-01-31
KR20020008847A (ko)	2002-01-31
ATE337008T1 (de)	2006-09-15
NO324230B1 (no)	2007-09-10
HK1048444A1 (en)	2003-04-04
JP2003500441A (ja)	2003-01-07
CY1109472T1 (el)	2012-05-23
MY135627A (en)	2008-05-30
ES2219342T3 (es)	2004-12-01
KR100683367B1 (ko)	2007-02-15
DK1736158T3 (da)	2009-11-02
EP1410800B1 (de)	2006-08-23
PL199650B1 (pl)	2008-10-31
PL352373A1 (en)	2003-08-25
DE60009697D1 (de)	2004-05-13
DE60009697T2 (de)	2005-04-14
PT1736158E (pt)	2009-11-11
SI1185272T1 (en)	2004-12-31
PL200490B1 (pl)	2009-01-30
HU229059B1 (en)	2013-07-29
ATE263564T1 (de)	2004-04-15
TW518218B (en)	2003-01-21
EP1185272B1 (de)	2004-04-07
AU5066300A (en)	2000-12-18
IL146707A (en)	2007-06-03

Publication	Publication Date	Title
DE60030338D1 (de)	2006-10-05	Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen Salzen
ATE551322T1 (de)	2012-04-15	3-z-1-(4-(n-((4-methylpiperazin-1- yl)methylcarbonyl)-n-methylamino)anilino)1- phenylmethylen-6-methoxycarbonyl-2- indolinonmonoethansulfonat und dessen verwendung als pharmazeutische zusammensetzung
DE60136736D1 (de)	2009-01-08	Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose
DE60237580D1 (de)	2010-10-21	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
NO942977D0 (no)	1994-08-11	Piperazin og piperidinderivater og anvendelse derav som antipsykotiske midler
EE200200442A (et)	2003-12-15	Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks
DE60138768D1 (de)	2009-07-02	Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
ATE305933T1 (de)	2005-10-15	Piperazin derivate
DE69917478D1 (de)	2004-06-24	Piperazine und piperidine derivate
ATE384695T1 (de)	2008-02-15	Carbamat caspase inhibitoren und deren verwendung
DE60010538D1 (de)	2004-06-17	Kosmetische Tensid-Präparate und deren Verwendung
NO984380L (no)	1999-03-25	Nye piperazin og piperidinforbindelser
DE60021507D1 (de)	2005-09-01	Uracilverbindungen und deren Verwendung
EE200100498A (et)	2002-12-16	1,4-asendatud piperasiin-, 1,4-asendatud piperidiin- ja 1-asendatud 4-alkülidenüülpiperidiinühendidning nende raviotstarbeline kasutamine
DK0839146T3 (da)	2000-11-20	Piperazinderivater og deres anvendelse som 5-HT1A-antagonister
ATE323685T1 (de)	2006-05-15	Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60001725D1 (de)	2003-04-24	Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE250339T1 (de)	2003-10-15	Dormanz-brechende zusammenstezung und deren verwendung
DE60125374D1 (de)	2007-02-01	Bisacrylamid enthaltende dentalmassen und deren verwendung
DE60210696D1 (de)	2006-05-24	Optisch aktive 4-(tert-Butoxycarbonyl)piperazin Derivate und Verfahren zu ihrer Herstellung
EP1137412A4 (de)	2002-04-03	Substituierte stickstoffhaltige heterocyclische verbindungen und deren therapeutische verwendung
NO950560L (no)	1995-08-17	Piperazinderivater, deres fremstilling og terapautiske anvendelse
EP1311282A4 (de)	2005-07-13	Hochaffine integrinpolypeptide und deren verwendung

Legal Events

Date	Code	Title	Description
2007-09-20	8364	No opposition during term of opposition